Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Avalo Therapeutics’ disclosures can feel like decoding a scientific journal—dozens of pages on IL-1B pathways, cash burn projections and clinical trial risk factors hide the details investors need. If you’ve ever wondered, “How do I quickly find insider trades or the latest BTLA agonist updates in Avalo’s 10-K?” you’re not alone.
Stock Titan’s AI-powered platform turns those dense documents into clear, actionable insights. Open a 10-K and our engine highlights pipeline milestones, R&D expenses and going-concern language in plain English. Need the most recent Avalo Therapeutics quarterly earnings report 10-Q filing? It’s here with trend charts on cash runway. A sudden 8-K material event explained? We flag it within minutes of EDGAR release. And every Avalo Therapeutics insider trading Form 4 transaction flows into real-time dashboards so you can monitor executive stock moves before the market reacts.
Whether you track dilution risk through shelf registrations, compare AVTX-009 study costs quarter-over-quarter or follow Avalo Therapeutics executive stock transactions Form 4, our coverage spans every form: 10-K annual reports, 10-Q quarterlies, 8-K event filings, S-3 offerings, proxy statements on executive compensation and more.
- Avalo Therapeutics annual report 10-K simplified—pipeline status, license agreements, risk factors.
- Avalo Therapeutics Form 4 insider transactions real-time—who bought or sold shares and when.
- Avalo Therapeutics earnings report filing analysis—AI summaries of trial spending and cash use.
No more hunting through footnotes. With Stock Titan you’re always one click away from understanding Avalo Therapeutics SEC documents with AI clarity.
Avalo Therapeutics reported a clinical milestone: it has completed enrollment in its Phase 2 LOTUS Trial evaluating AVTX-009 for hidradenitis suppurativa. The company disclosed the update via a press release furnished as Exhibit 99.1 to this report, dated October 29, 2025. This marks the transition from recruitment to data collection and analysis for the study.
Avalo Therapeutics insider stock option grant to Chief Business Officer — Boyd Taylor received a stock option on The option covers 275,000 shares of common stock with an exercise price of
Boyd Taylor, identified as Chief Business Officer and a director, filed an initial Form 3 for Avalo Therapeutics, Inc. (AVTX) reporting the event date 10/01/2025. The filing states no securities are beneficially owned by the reporting person. The form was signed under power of attorney by Donald R. Reynolds on 10/06/2025. The submission confirms an initial disclosure with no ownership to report.
Avalo Therapeutics director Kevin Robert Lind was granted a stock option on 10/01/2025 to buy 40,200 shares of common stock at an exercise price of $12.96. The option becomes exercisable in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the director's continued service. The option expires on 10/01/2035 and the reporting Form 4 was filed on 10/02/2025 by power of attorney. The grant is reported as a direct holding and shows 40,200 shares underlying the derivative security following the transaction.
Avalo Therapeutics, Inc. (AVTX) director Kevin Robert Lind filed an initial Form 3 reporting that he does not beneficially own any securities of the issuer. The Form 3 lists the qualifying event date as 10/01/2025 and is signed by Donald R. Reynolds by power of attorney on 10/02/2025. The filing gives the reporter's address as 1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087.
Rita Jain, a director of Avalo Therapeutics, Inc. (AVTX), reported a grant of stock options on 09/30/2025. The filing shows the grant of 1,572 stock options with an exercise price of $12.71. The options were reported as 100% vested in the explanatory note. The options are linked to 1,572 underlying shares and are held directly by Ms. Jain following the transaction. The derivative table lists an expiration or related date of 09/30/2035, and the reported transaction was signed by a power of attorney on 10/02/2025.
Patrick J. Crutcher filed an amended Schedule 13G reporting beneficial ownership of 549,467 shares of Avalo Therapeutics, Inc. common stock, representing 4.2% of the 13,152,356 shares outstanding cited from the issuer's August 7, 2025 prospectus. The filing shows the Reporting Person holds sole voting and dispositive power over all reported shares and indicates the position is not held to change or influence control of the company. The filing includes the Reporting Person's address in Atlanta, GA, and a certification that the securities were not acquired in connection with any control transaction.
FAQ
What is the current stock price of Avalo Therapeutics (AVTX)?
What is the market cap of Avalo Therapeutics (AVTX)?
